Quantoom and eTheRNA will work together to build an advanced, small footprint technology platform for the production of affordable RNA-based therapies, that can be used either within existing facilities or rapidly deployed to areas of urgent need
eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies with in-house GMP certified production and process development capabilities, and Quantoom Biosciences, a biotech aiming to improve access to essential medicines through innovative bioproduction methods, are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material.
Quantoom and eTheRNA will work together to build an advanced, small footprint technology platform for the production of affordable RNA-based therapies, that can be used either within existing facilities or rapidly deployed to areas of urgent need. Unlike large and costly existing RNA production plants, the RPS will manufacture RNA small modular units, which can be shipped easily across multiple geographic regions.
The RPS is intended to be scaled seamlessly from small scale preclinical batches to mass production of GMP-grade RNA. The only requirement will be for the RPS to be located inside a suitable cleanroom with an uninterrupted utility supply.
The RPS is intended to be scaled seamlessly from small scale preclinical batches to mass production of GMP-grade RNA
Under the terms of the agreement, eTheRNA will transfer manufacturing technology to Quantoom with all materials and data necessary for the development of the novel RPS.
Following completion of the RPS, Quantoom will be responsible for commercialisation of the system on a worldwide basis, with sales-related royalties payable to eTheRNA.
International sales and distribution are expected to commence in 2023 following RPS production in Belgium.
Bernard Sagaert, SVP Manufacturing and COO of eTheRNA, said: "This cooperation aligns with our goals for RNA production; namely cost reduction, process scalability from small to large scale, portability and process automation. Currently, the global supply of RNA is hampered by the lack of dedicated production facilities and by the cost of constructing new plants."
"The RPS will revolutionise the way RNA is produced and distributed globally and we are excited to be able to work with a leading developer and manufacturer like Quantoom to bring this vision to the market," Sagaert added.
Quantoom Biosciences is a team of scientists, engineers and clinicians bringing radical innovation to vaccines and therapeutics production, led by José Castillo co-founder of Univercells. A serial entrepreneur, José previously co-founded Artelis, where he invented the iCellis bioreactor, which became industry standard for cell and gene therapy.